ATE337333T1 - Ophthalmische arzneimittelzusammenstellung - Google Patents

Ophthalmische arzneimittelzusammenstellung

Info

Publication number: ATE337333T1
Authority: AT; Austria
Prior art keywords: ophthalmic; present; leu; gly; met
Prior art date: 1996-06-26

Application number

AT97926223T

Other languages

English (en)

Inventor

Teruo Nishida

Masatsugu Nakamura

Katsuhiko Nakata

Original Assignee

Santen Pharmaceutical Co Ltd

Teruo Nishida

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-26

Filing date

1997-06-11

Publication date

2006-09-15

1997-06-11 Application filed by Santen Pharmaceutical Co Ltd, Teruo Nishida filed Critical Santen Pharmaceutical Co Ltd

2006-09-15 Application granted granted Critical

2006-09-15 Publication of ATE337333T1 publication Critical patent/ATE337333T1/de

Links

239000000203 mixture Substances 0.000 title abstract 3
239000004480 active ingredient Substances 0.000 abstract 3
JIJRURCWBONLPN-BZSNNMDCSA-N L-Phe-Gly-L-Leu-L-Met-NH2 Chemical compound CSCC[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 JIJRURCWBONLPN-BZSNNMDCSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000021921 corneal disease Diseases 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
108010051137 phenylalanyl-glycyl-leucyl-methioninamide Proteins 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 abstract 1
230000005012 migration Effects 0.000 abstract 1
238000013508 migration Methods 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT97926223T 1996-06-26 1997-06-11 Ophthalmische arzneimittelzusammenstellung ATE337333T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP16561296A JP3191038B2 (ja)	1996-06-26	1996-06-26	眼科用医薬組成物

Publications (1)

Publication Number	Publication Date
ATE337333T1 true ATE337333T1 (de)	2006-09-15

Family

ID=15815677

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97926223T ATE337333T1 (de)	1996-06-26	1997-06-11	Ophthalmische arzneimittelzusammenstellung

Country Status (7)

Country	Link
US (1)	US6221846B1 (de)
EP (1)	EP0914827B1 (de)
JP (1)	JP3191038B2 (de)
AT (1)	ATE337333T1 (de)
DE (1)	DE69736554T2 (de)
ES (1)	ES2268730T3 (de)
WO (1)	WO1997049419A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7273618B2 (en)	1998-12-09	2007-09-25	Chiron Corporation	Method for administering agents to the central nervous system
AU2173400A (en) *	1998-12-09	2000-06-26	Chiron Corporation	Method for administering agents to the central nervous system
US7071166B2 (en)	2000-08-10	2006-07-04	Santen Pharmacetical Co., Ltd.	Skin wound healing promoters
JP4253743B2 (ja) *	2001-12-03	2009-04-15	輝夫西田	新規ペプチドおよびその医薬用途
TWI305778B (en)	2001-12-03	2009-02-01	Nishida Teruo	Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
JP4313033B2 (ja) *	2002-12-27	2009-08-12	株式会社日本点眼薬研究所	眼科用治療組成物
WO2007062060A2 (en)	2005-11-22	2007-05-31	Ted Reid	Methods and compositions using substance p to promote wound healing
BR112012006187A2 (pt) *	2009-09-25	2019-09-24	Santen Pharmaceutical Co., Ltd.	colírio, e método para estabilizar um colírio,tendo um excelente efeito sobre a promoção da cura de um distúrbio da córnea
CA2779417A1 (en) *	2009-11-11	2011-05-19	Yamaguchi University	Therapeutic agent for gastrointestinal disease
SG11201706819RA (en) *	2015-02-25	2017-09-28	Tsung-Chuan Ho	Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
KR101869783B1 (ko) *	2016-08-17	2018-06-22	(주)진셀팜	미백 활성이 우수한 펩타이드, 및 이의 용도
WO2019061491A1 (en) *	2017-09-30	2019-04-04	Pro Sunfun Biotech Research And Development Co., Ltd.	PEPTIDE FOR OCULAR CARE, COMPOSITION AND METHOD OF USE THEREOF
CN109912685B (zh) *	2017-12-13	2022-05-06	三凡生技研发股份有限公司	眼睛保护胜肽及其组合物及使用该胜肽的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3862114A (en)	1971-11-22	1975-01-21	Ici Australia Ltd	Analogs of substance p
EP0176436A3 (de) *	1984-09-26	1987-12-16	Merck & Co. Inc.	Analoge der Verbindung P und von Eledoisin
US4885163A (en)	1987-02-24	1989-12-05	Eli Lilly And Company	Topical use of IGF-II for wound healing
NZ226171A (en)	1987-09-18	1990-06-26	Ethicon Inc	Gel formulation containing polypeptide growth factor
US5104787A (en)	1990-03-05	1992-04-14	Lindstrom Richard L	Method for apparatus for a defined serumfree medical solution useful for corneal preservation
US5616562A (en)	1990-04-27	1997-04-01	Murphy; Christopher J.	Methods and compositions using substance P to promote wound healing
GB9113219D0 (en) *	1991-06-19	1991-08-07	Fujisawa Pharmaceutical Co	Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
JPH0525001A (ja)	1991-07-08	1993-02-02	L Lyndstrom Richard	血清不含有医療用溶液および眼組織の品質を高める方法
US6310040B1 (en)	1991-11-08	2001-10-30	Cephalon, Inc.	Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US5545617A (en)	1993-11-12	1996-08-13	The Schepens Eye Research Institute, Inc.	Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion

1996
- 1996-06-26 JP JP16561296A patent/JP3191038B2/ja not_active Expired - Fee Related
1997
- 1997-06-11 US US09/202,820 patent/US6221846B1/en not_active Expired - Lifetime
- 1997-06-11 ES ES97926223T patent/ES2268730T3/es not_active Expired - Lifetime
- 1997-06-11 EP EP97926223A patent/EP0914827B1/de not_active Expired - Lifetime
- 1997-06-11 AT AT97926223T patent/ATE337333T1/de not_active IP Right Cessation
- 1997-06-11 WO PCT/JP1997/002015 patent/WO1997049419A1/ja not_active Ceased
- 1997-06-11 DE DE69736554T patent/DE69736554T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2268730T3 (es)	2007-03-16
EP0914827A4 (de)	1999-08-04
DE69736554D1 (de)	2006-10-05
JP3191038B2 (ja)	2001-07-23
EP0914827A1 (de)	1999-05-12
DE69736554T2 (de)	2007-08-23
WO1997049419A1 (en)	1997-12-31
US6221846B1 (en)	2001-04-24
EP0914827B1 (de)	2006-08-23
JPH1017489A (ja)	1998-01-20

Similar Documents

Publication	Publication Date	Title
BG60102B2 (bg)	1993-10-29	Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
ATE337333T1 (de)	2006-09-15	Ophthalmische arzneimittelzusammenstellung
BR0214757A (pt)	2004-09-14	Formulações farmacêuticas de derivados de platina
HUP0102899A2 (hu)	2002-03-28	Eljárás gyulladásgátló, különösen fertőtlenítő hatású és/vagy sebgyógyulást elősegítő szerek alsó légutakba történő beadására szolgáló készítmények előállítására
ATE202926T1 (de)	2001-07-15	Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
BR9107124A (pt)	1993-11-09	Novos derivados de acido hidroxamico e de n-hidroxiureia e seu uso
NO975962D0 (no)	1997-12-18	Legemiddelpreparat som omfatter albumin som aktiv bestanddel
YU2494A (sh)	1997-01-08	Farmaceutska formulacija za tretiranje zavisnosti od nikotina
DE69501419D1 (de)	1998-02-19	Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol
RU93032613A (ru)	1996-06-20	Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DK0969843T3 (da)	2002-10-07	Antitussive formuleringer indeholdende theobromin
DE69229318D1 (de)	1999-07-08	Hydrierte Rizinusöl-enthaltende injizierbare Formulierungen mit verlängerter Wirkstoffabgabe
ATE245900T1 (de)	2003-08-15	Pour-on formulierung enthaltend polymerische material, glykole und glyzeriden
FI913034A0 (fi)	1991-06-20	Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning.
HUP9802897A2 (hu)	2000-11-28	Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
ATE458471T1 (de)	2010-03-15	Formulierungen mit povidon-iod zur behandlung von wunden
IE780217L (en)	1978-08-21	1,3,5-triazine-2,6-dione derivatives
ATE311897T1 (de)	2005-12-15	Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
US5993841A (en)	1999-11-30	Pharmaceutical composition and methods for using it
EA200400348A1 (ru)	2005-04-28	Цисплатиновые составы пониженной токсичности и способы их применения
NO950177L (no)	1995-01-17	Farmakologisk aktive erivater
TR200201654T2 (tr)	2002-12-23	Benzamidin türevleri.
UA41326C2 (uk)	2001-09-17	Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
EP0756870A2 (de)	1997-02-05	Pharmazeutische Zusammensetzungen zur topischem Gebrauch enthaltend Ketoprofen
DE68916443D1 (de)	1994-07-28	Arzneimittel zur behandlung von kryptosporidiose.

Legal Events

Date	Code	Title	Description
2007-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties